- Author: Nader Kamangar, MD, FACP, FCCP, FCCM; Chief Editor: Ryland P Byrd, Jr, MD more...
Bacterial pneumonia (see the image below) is caused by a pathogenic infection of the lungs and may present as a primary disease process or as the final, fatal disorder primarily in an individual who is already debilitated.
Signs and symptoms
Cough, particularly cough productive of sputum, is the most consistent presenting symptom of bacterial pneumonia and may suggest a particular pathogen, as follows:
Streptococcus pneumoniae: Rust-colored sputum
Pseudomonas, Haemophilus, and pneumococcal species: May produce green sputum
Klebsiella species pneumonia: Red currant-jelly sputum
Anaerobic infections: Often produce foul-smelling or bad-tasting sputum
Signs of bacterial pneumonia may include the following:
Hyperthermia (fever, typically >38°C)  or hypothermia (< 35°C)
Tachypnea (>18 respirations/min)
Use of accessory respiratory muscles
Tachycardia (>100 bpm) or bradycardia (< 60 bpm)
Altered mental status
Physical findings may include the following:
Adventitious breath sounds, such as rales/crackles, rhonchi, or wheezes
Decreased intensity of breath sounds
Dullness to percussion
Pleural friction rub
Examination findings that may indicate a specific etiology include the following:
Bradycardia: May indicate a Legionella etiology
Periodontal disease: May suggest an anaerobic and/or polymicrobial infection
Bullous myringitis: May indicate Mycoplasma pneumoniae infection
Cutaneous nodules: May suggest Nocardia infection
Decreased gag reflex: Suggests risk for aspiration
See Clinical Presentation for more detail.
Tools to assess the severity of disease and risk of death include the PSI/PORT (ie, pneumonia severity index/Patient Outcomes Research Team score), the CURB-65 (ie, confusion, urea, respiratory rate, blood pressure, and age >65 years) system, and the APACHE (ie, acute physiology and chronic health evaluation), among others.
The following laboratory tests are also useful for assessing illness severity:
Serum chemistry panel
Arterial blood gas (ABG) determination
Venous blood gas determination (central venous oxygen saturation)
Complete blood count (CBC) with differential
Serum free cortisol value
Serum lactate level
Sputum Gram stain and culture should be performed before initiating antibiotic therapy. A single predominant microbe should be noted at Gram staining, although mixed flora may be observed with anaerobic infection caused by aspiration.
Chest radiography: The criterion standard for establishing the diagnosis of pneumonia
Chest computed tomography scanning
Lung tissue can be visually evaluated and bronchial washing specimens can be obtained with the aid of a fiberoptic bronchoscope. Protected brushings and bronchoalveolar lavage (BAL) can be performed for fluid analysis and cultures.
This is an essential procedure in patients with a parapneumonic pleural effusion. Analysis of the fluid allows differentiation between simple and complicated effusions.
Sputum, serum, and/or urinary antigen tests
Immune serologic tests
Histologic inflammatory lung changes vary according to whether the patient has lobar pneumonia, bronchopneumonia, or interstitial pneumonia.
See Workup for more detail.
The mainstay of drug therapy for bacterial pneumonia is antibiotic treatment. First-line antimicrobials for S pneumoniae, the most prevalent cause of bacterial pneumonia, are, for the penicillin-susceptible form of the bacterium, penicillin G and amoxicillin. For the penicillin-resistant form of S pneumoniae, first-line agents are chosen on the basis of sensitivity.
Supportive measures include the following:
Analgesia and antipyretics
Intravenous fluids (and, conversely, diuretics), if indicated
Pulse oximetry with or without cardiac monitoring, as indicated
Positioning of the patient to minimize aspiration risk
Respiratory therapy, including treatment with bronchodilators and N-acetylcysteine
Suctioning and bronchial hygiene
Ventilation with low tidal volumes (6 mL/kg of ideal body weight) in patients requiring mechanical ventilation secondary to bilateral pneumonia or acute respiratory distress syndrome (ARDS) 
Systemic support: May include proper hydration, nutrition, and mobilization
Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar air spaces with exudate, inflammatory cells, and fibrin is characteristic. Infection by bacteria or viruses is the most common cause, although infection by other micro-orgamisms such as rickettsiae, fungi and yeasts, and mycobacteria may occur. (See the images below.)
Bacterial pneumonia is caused by a pathogenic infection of the lungs and may present as a primary disease process or as the final coup de grace in the individual who is already debilitated. For example, a historical review of the 1918-19 influenza pandemic suggests that the majority of deaths were not a direct effect of the influenza virus, but they were from bacterial coinfection.
Discussion of bacterial pneumonia involves classification and categorization schemes based on various characteristics of the illness, such as anatomic or radiologic distribution, the setting, or mechanism of acquisition, and the pathogen responsible. A major part of what distinguishes these various categories from each other is the varying risk of exposure to multidrug-resistant (MDR) organisms.[6, 7, 8]
Anatomic or radiologic distribution of pneumonia includes the following (see Chest Radiography for details):
Lobar - Known as focal or nonsegmental pneumonia (see the images below)
Interstitial (focal diffuse)Bacterial pneumonia. Radiographic images in a patient with right upper lobe pneumonia. Note the increased anteroposterior chest diameter, which is suggestive of chronic obstructive pulmonary disease (COPD).Bacterial pneumonia. Radiographic images in a patient with bilateral lower lobe pneumonia. Note the spine sign, or loss of progression of radiolucency of the vertebral bodies
The setting of pneumonia includes the community, institutional (healthcare/nursing home setting), and nosocomial (hospital).
Community-acquired pneumonia (CAP) is defined as pneumonia that develops in the outpatient setting or within 48 hours of admission to a hospital. CAP should not meet the criteria for healthcare-associated pneumonia (HCAP), as defined below.
Go to Community-Acquired Pneumonia for complete information on this topic.
Institutional-acquired pneumonia (IAP) includes HCAP and nursing home–associated pneumonia (NHAP).
HCAP is defined as pneumonia that develops in the outpatient setting or within 48 hours of admission to a hospital in patients with increased risk of exposure to MDR bacteria as a cause of infection. Risk factors for exposure to MDR bacteria in HCAP include the following:
Hospitalization for two or more days in an acute care facility within 90 days of current illness
Exposure to antibiotics, chemotherapy, or wound care within 30 days of current illness
Residence in a nursing home or long-term care facility
Hemodialysis at a hospital or clinic
Home nursing care (infusion therapy, wound care)
Contact with a family member or other close person with infection due to MDR bacteria
NHAP is generally included in the category of HCAP because of the high incidence of infection with gram-negative bacilli and Staphylococcus aureus. However, some authors accept NHAP as a separate entity because of distinct epidemiologic associations with infection in nonhospital healthcare settings. Pneumonia in patients in nursing homes and long-term care facilities has been associated with greater mortality than in patients with CAP. These differences may be due to factors such as disparities in functional status, likelihood of exposure to infectious agents, and variations in pathogen virulence, among others.
It is important to note that nursing home patients with pneumonia are less likely to present with classic signs and symptoms of the typical pneumonia presentation, such as fever, chills, chest pain, and productive cough, but instead these individuals often have delirium and altered mental status. Thus, the degree to which the HCAP definition applies to such settings is not yet clear.[6, 7]
Go to Nursing Home Acquired Pneumonia for complete information on this topic.
Nosocomial infections are generally described as those acquired in the hospital setting. The term nosocomial pneumonia has evolved into the more succinct clinical entities of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). However, the term nosocomial pneumonia still has an appropriate place in the descriptive language of pneumonia. Nosocomial infections have been viewed as a "tribute to pay to the more aggressive management of the population, characterized by the use of sophisticated technologies and invasive devices," an important consideration in the pulmonary care of critically ill patients.
HAP is defined as pneumonia that develops at least 48 hours after admission to a hospital and, as in HCAP, is characterized by increased risk of exposure to MDR organisms, as well as gram-negative organisms. Risk factors for exposure to such organisms in HAP include the following :
Antibiotic therapy within 90 days of the hospital-acquired infection
Current length of hospitalization of five days or more
High frequency of antibiotic resistance in the local community or within the specific hospital unit
Immunosuppressive disease or therapy
Presence of HCAP risk factors for exposure to MDR bacteria
Common mechanisms for the acquisition of pneumonia include ventilator use and aspiration.
VAP is defined as pneumonia that develops more than 48 hours after endotracheal intubation or within 48 hours of extubation. Risk factors for exposure to MDR bacteria that cause VAP are the same as those for HCAP and/or HAP.[6, 8] VAP may occur in as many as 10-20% of patients who are on ventilators for more than 48 hours.
Go to Ventilator-Associated Pneumonia for complete information on this topic.
Aspiration pneumonia develops after the inhalation of oropharyngeal secretions and colonized organisms. Although organisms frequently implicated in CAP, such as Haemophilus influenzae and Streptococcus pneumoniae, can colonize the nasopharynx and oropharynx and their aspiration can contribute to the development of CAP, the term aspiration pneumonia refers specifically to the development of an infectious infiltrate in patients who are at increased risk of oropharyngeal aspiration.
Patients may be at increased risk of aspiration and/or the development of aspiration pneumonia for a number of reasons, as follows:
Decreased ability to clear oropharyngeal secretions - Poor cough or gag reflex, impaired swallowing mechanism (eg, dysphagia in stroke patients), impaired ciliary transport (eg, from smoking)
Increased volume of secretions
Increased bacterial burden of secretions
Critically ill patients are at notably increased risk of aspiration due to the following:
The challenge of appropriate, risk-minimizing positioning
Impaired cough/gag/swallow reflexes (illness- or drug-induced)
Impaired immune response
Historically, the bacteria implicated in aspiration pneumonia have been the anaerobic oropharyngeal colonizers such as Peptostreptococcus, Bacteroides, Fusobacterium, and Prevotella species. However, now evident is that the vast majority of cases of aspiration pneumonia result from the same pathogens implicated in CAP and HAP, depending on the setting in which the aspiration event occurred. The clinical course of aspiration pneumonia is, thus, similar to that of CAP or HAP. However, recurrence of aspiration pneumonia is common unless the risk factors for underlying aspiration are treated or minimized.
Go to Aspiration Pneumonia for complete information on this topic.
The causes for the development of pneumonia are extrinsic or intrinsic, and various bacterial causes are noted. Extrinsic factors include exposure to a causative agent, exposure to pulmonary irritants, or direct pulmonary injury. Intrinsic factors are related to the host. Loss of protective upper airway reflexes allows aspiration of contents from the upper airways into the lung. Various causes for this loss include altered mental status due to intoxication and other metabolic states and neurologic causes, such as stroke and endotracheal intubation.
Bacteria from the upper airways or, less commonly, from hematogenous spread, find their way to the lung parenchyma. Once there, a combination of factors (including virulence of the infecting organism, status of the local defenses, and overall health of the patient) may lead to bacterial pneumonia. The patient may be made more susceptible to infection because of an overall impairment of the immune response (eg, human immunodeficiency virus [HIV] infection, chronic disease, advanced age) and/or dysfunction of defense mechanisms (eg, smoking, chronic obstructive pulmonary disease [COPD], tumors, inhaled toxins, aspiration). Poor dentition or chronic periodontitis is another predisposing factor.
Thus, during pulmonary infection, acute inflammation results in the migration of neutrophils out of capillaries and into the air spaces, forming a marginated pool of neutrophils that is ready to respond when needed. These neutrophils phagocytize microbes and kill them with reactive oxygen species, antimicrobial proteins, and degradative enzymes. They also extrude a chromatin meshwork containing antimicrobial proteins that trap and kill extracellular bacteria, known as neutrophil extracellular traps (NETs). Various membrane receptors and ligands are involved in the complex interaction between microbes, cells of the lung parenchyma, and immune defense cells.
General mechanisms of increased virulence include the following:
Genetic flexibility allowing the development of resistance to various classes of antibiotics
Flagellae and other bacterial appendages that facilitate spread of infection
Capsules resistant to attack by immune defense cells and that facilitate adhesion to host cells
Quorum sensing systems allow coordination of gene expression based on complex cell-signaling for adaptation to the local cellular environment
The following are examples of organism-specific virulence factors:
Streptococcus pneumoniae – Pneumolysin, a multifunctional virulence factor, is cytotoxic to respiratory epithelium and endothelium by disrupting pulmonary tissue barriers. This factor directly inhibits immune and inflammatory cells and activates complement, decreasing the clearance of the bacteria from the lung. 
Pseudomonas aeruginosa - Pili play important role in the attachment to host cells. A type III secretion system allows injection of toxins into host cells. 
Deficits in various host defenses and an inability to mount an appropriate acute inflammatory response can predispose patients to infection, as follows :
Deficits in neutrophil quantity, as in neutropenia
Deficits in neutrophil quality, as in chronic granulomatous disease
Deficiencies of complement
Deficiencies of immunoglobulins
With the recent H1N1 influenza virus pandemic, it is important to address the role that viral infection can have in bacterial pneumonia.
The association between infection with influenza virus and subsequent bacterial pneumonia became particularly apparent following the 1918 influenza pandemic, during which approximately 40-50 million people died. Historical investigations and current researchers argue that the vast majority of pulmonary-related deaths from past pandemic influenza viruses, most notably the pandemic of 1918, ultimately resulted from bacteriologic secondary or coinfection and poorly understood interactions between the infecting viral and bacterial organisms. Although influenza virus is the most commonly thought of agent in this co-infective context, other respiratory viruses, such as respiratory syncytial virus (RSV), parainfluenza viruses, adenovirus, and rhinoviruses, may also predispose to secondary bacterial infection.
The classic explanation behind the viral-bacterial interplay focuses on the disruption of the respiratory epithelium by the virus, providing an opportinistic environment for bacterial infection. However, evidence depicts much more complex and possibly synergistic interactions between viruses and bacteria, including alteration of pulmonary physiology, downregulation of the host immune defense, changes in expression of receptors to which bacteria adhere, and enhancement of the inflammatory process.
Although pneumonia may be caused by myriad pathogens, a limited number of agents are responsible for most cases,[18, 3, 19, 20] Most authors categorize bacterial pneumonias by their infectious agents, which include pneumococcal agents; Haemophilus influenzae; Klebsiella, Staphylococcus, and Legionella species; gram-negative organisms; and aspirated micro-organisms. Inhalation of infectious aerosols is probably the most common mode of infection. Some agents, notably Staphylococcus species, may be spread hematogenously.
Coinfection with H1N1 influenza increases the risk of secondary bacterial pneumonia, with S pneumoniae the most likely coinfection. However, pregnant patients with H1N1 influenza in the 2009 pandemic were at increased risk of developing secondary Klebsiella pneumonia with poor clinical outcome.
Other risk factors include local lung pathologies (eg, tumors, chronic obstructive pulmonary disease [COPD], bronchiectasis), chronic gingivitis and periodontitis, and smoking which impairs resistance to infection. Furthermore, any individual with an altered sensorium (eg, seizures, alcohol or drug intoxication) or central nevous system (CNS) impairment (eg, stroke) may have a reduced gag reflex, which allows aspiration of stomach or oropharyngeal contents and contributes to the development of aspiration pneumonias.
Although several of the organisms discussed in this section may be implicated in pneumonia, only a few of them are responsible for the vast majority of cases.
Gram-positive bacteria that can cause pneumonia include the following:
Streptococcus pneumoniae: This organism is a facultative anaerobe identified by its chainlike staining pattern. Pneumococcosis is by far the most common cause of typical bacterial pneumonia.
Staphylococcus aureus: S aureus is a facultative anaerobe identified by its clusterlike staining pattern. S aureus pneumonia is observed in intravenous drug abusers (IVDAs) and individuals with debilitating disorders. In patients who abuse intravenous drugs, the infection probably is spread hematogenously to the lungs from contaminated injection sites. Methicillin-resistant S aureus (MRSA) has had a large impact on empiric antibiotic choices at many institutions.
Enterococcus ( E faecalis, E faecium): These organisms are group D streptococci that are well-known normal gut florae that can be identified by their pair-and-chain staining pattern. The emergence of vancomycin-resistant Enterococcus (VRE) is indicative of the importance of appropriate antibiotic use.
Actinomyces israelii: This is a beaded, filamentous anaerobic organism that grows as normal flora in the gastrointestinal (GI) tract and can colonize the oral cavity in patients with periodontal disease. A israelii is known to form abscesses and sulfur granules.
Nocardia asteroides: N asteroides is a weakly gram-positive, partially acid-fast bacillus (AFB) that forms beaded, branching, thin filaments. It is known to cause lung abscesses and cavitations. Erosion into the pleura can also occur, resulting in hematologic spread of the organism.
Gram-negative pneumonias occur most often in individuals who are debilitated, immunocompromised, or recently hospitalized. Individuals living in long-term care facilities where other residents are intubated are also at risk for these infections. Gram-negative bacteria include the following:
Pseudomonas aeruginosa: P aeruginosa is an aerobic, motile bacillus often characterized by its distinct (grapelike) odor.
Klebsiella pneumoniae: K pneumoniae is a facultatively anaerobic, encapsulated bacillus that can lead to an aggressive, necrotizing, lobar pneumonia. Patients with chronic alcoholism, diabetes, or COPD are at increased risk for infection with this organism.
Haemophilus influenzae: H influenzae is an aerobic bacillus that comes in both encapsulated and nonencapsulated forms. Several major subtypes have been identified, which have varying levels of pathogenicity. Encapsulated type B (HiB) is known to be particularly virulent, although routine vaccination against this subtype has decreased the prevalence of severe disease caused by H influenzae. Infection with this bacteria is more common in patients with COPD.
Escherichia coli: E coli is a facultatively anaerobic, motile bacillus. It is well known to colonize the lower GI tract and produce the essential vitamin K.
Moraxella catarrhalis: M catarrhalis is an aerobic diplococcus known as a common colonizer of the respiratory tract.
Acinetobacter baumannii: A baumannii is a pathogen that has been well described in the context of ventilator-associated pneumonia (VAP).
Francisella tularensis: F tularensis is the causative agent of tularemia or rabbit fever. F tularensis is a facultative intracellular bacterium that multiplies within macrophages and that is typically transmitted to humans via a tick bite. Its reservoir animals include rodents, rabbits, and hares. F tularensis can also be transmitted in an airborne manner or contracted from handling dead, infected animals. It is commonly spoken of in terms of its potential use as a biologic weapon. 
Bacillus anthracis: B anthracis is the agent responsible for inhalational anthrax.
Yersinia pestis: Y pestis infection is better known as the black plague. It is the most commonly accepted cause of the pandemic known as the bubonic plague. This organism can also cause the pneumonic plague. The pneumonic plague causes a lung infection by the direct inhalation of aerosolised plague bacteria or, secondary, when the organism spreads to the lungs from the bloodstream. Pneumonic plague is, therefore, not exclusively vector-borne like bubonic plague. Instead, it can be spread from person to person. Other members of the Yersinia family are responsible for a wide variety of infectious presentations.
Atypical organisms are generally associated with a milder form of pneumonia, the so-called "walking pneumonia." A feature that makes these organisms atypical is the inability to detect them on Gram stain or to cultivate them in standard bacteriologic media.[18, 3] Atypical organisms include the following:
Mycoplasma species: The mycoplasmas are the smallest known free-living organisms in existence. These organisms lack cell walls (and therefore are not apparent after Gram stain) but have protective 3-layered cell membranes.
Chlamydophila species ( C psittaci, C pneumoniae): Psittacosis, also known as parrot disease or parrot fever, is caused by C psittaci and is associated with the handling of various types of birds.
Legionella species: Legionella species are gram-negative bacteria found in freshwater and are known to grow in complex water distribution systems. Institutional water contamination is frequently noted in endemic outbreaks. Legionella pneumophila is the causative agent of the majority of Legionnaires' disease. Other Legionella species are known to infect the lower respiratory system.
Coxiella burnetii: C burnetii is the causative agent of Q fever. It is spread from animals to humans; person-to-person transmission is unusual. Animal reservoirs typically include cats, sheep, and cattle.
Bordetella pertussis: B pertussis is the agent responsible for pertussis or whooping cough.
Pneumonia due to anaerobes typically results from aspiration of oropharyngeal contents, as previously mentioned. These infections tend to be polymicrobial and may consist of the following anaerobic species, some of which have already been discussed above: Klebsiella, Peptostreptococcus, Bacteroides, Fusobacterium, and Prevotella.
In the United States, acute lower respiratory tract infections cause more disease and death than any other infection. In fact, these infections also cause a greater burden of disease worldwide than human immunodeficiency virus (HIV) infection, malaria, cancer, or heart attacks. The prevalence of various pathogens and epidemiology of disease vary widely between countries and regions, making precise discussion of international disease burden difficult.
More than three million cases occur annually in the United States. Pneumonia is more prevalent during the winter months and in colder climates. This condition is most likely from viral upper and lower respiratory infections, which increase in winter and result in impaired host defenses to bacterial superinfection.
The most common etiologies of community-acquired pneumonia (CAP) in the outpatient setting are as follows (in descending order of frequency): S pneumoniae, M pneumoniae, H influenzae, C pneumoniae, and respiratory viruses.
The most common etiologies of CAP in the non–intensive care unit (ICU) inpatient setting, in descending order of frequency, are as follows: S pneumoniae, M pneumoniae, C pneumoniae, H influenzae, Legionella species, aspiration, and respiratory viruses. Legionella pneumophila infections tend to occur sporadically and in local epidemic clusters. These infections usually arise in the summer and fall and may be found in the water condensed from air conditioning systems.
The most common etiologies of CAP in the ICU inpatient setting, in descending order of frequency, are as follows : S pneumoniae, S aureus, Legionella species, and Gram-negative bacilli.
Ventilator-associated pneumonia (VAP) notably develops in approximately 9-27% of all intubated patients and carries a mortality rate of 30-60%.[8, 24]
Race, sex, and age
Black men (26.6 deaths per 100,000 population) are more likely to die from pneumonia compared with white men (23 deaths per 100,000 population), whereas black (17.4 deaths per 100,000 population) and white women (18.2 deaths per 100,000 population) are almost equally likely to die from pneumonia.[25, 26]
The incidence of pneumonia is greater in males than in females but the total number of deaths due to pneumonia has been higher among females since the mid 1980s. However, females have age-adjusted death rates close to 30% lower than those in men, because the female population in the United States is larger than the male population. The age-adjusted death rates for females have been reported as 17.9 deaths per 100,000 population and 23.9 deaths per 100,000 population for males.[25, 26]
Advanced age increases the incidence of and the mortality from pneumonia. Comorbidity and a diminished immune response and defense against aspiration increase the risk of bacterial pneumonia. For individuals aged 65 years and older, pneumonia and influenza were the sixth leading cause of death in 2005.[25, 26] Close to 90% of deaths due to pneumonia and influenza occurred in this age group. In a 20-year US study, the average overall mortality rate in pneumococcal pneumonia with bacteremia was 20.3%. Patients older than 80 years of age had the highest mortality rate, which was 37.7%.
Generally, the prognosis is good in otherwise healthy patients with uncomplicated pneumonia. Advanced age, aggressive organisms (eg, Klebsiella, Legionella, resistant S pneumoniae), comorbidity, respiratory failure, neutropenia, and features of sepsis, alone or in combination, increase morbidity and mortality. Left untreated, pneumonia may have an overall mortality rate of more than 30%.
Even with appropriate treatment, the risk of mortality may be high if the host is ill or infirm. The Pneumonia Severity Index (PSI) may be used as a guide to determine a patient's mortality risk, but it tends to overestimate the actual risk in many cases (see Pneumonia severity index under Risk Stratification in Clinical Presentation). Particularly virulent organisms, such as Klebsiella and Legionella species, may confer a higher mortality rate.
In a study looking at microbial etiologies of CAP, S pneumoniae was present in the highest total number of deaths. However, gram-negative enteric bacilli, Pseudomonas, Staphylococcus aureus, and mixed etiologies had the highest mortality rates in those effected.
Morbidity may include destruction of lung tissue from infection with subsequent scarring. Affected areas may be incapable of gas exchange, reducing respiratory reserve. In a patient with pre-existing respiratory disease, the onset of bacterial pneumonia may result in a downward spiral of infections, further impairment of respiratory status, and repeated infections owing to reduced local and systemic immune responses. Bronchiectasis may be a sequela of bacterial pneumonia. Infections with Staphylococcus and Klebsiella organisms may result in subsequent bronchiectasis, especially if treatment is delayed.
Destroyed alveoli and small-to-medium airways may be replaced by dilated blind saccules filled with purulent material. Ongoing, chronic inflammation usually occurs in the surrounding area and may destroy local adjacent lung tissue over time. Empyema and lung abscess may occur as direct complications of bacterial pneumonia. Pneumonia has been associated with increased incidence of placental abruption in pregnant patients.
Patients should be encouraged to stop smoking, to avoid drinking alcohol to intoxication, and to keep their teeth in good repair. In addition, instruct patients at risk to receive appropriate influenza and pneumococcal immunizations.
Patients, particularly elderly and debilitated patients, should be instructed to seek prompt care should symptoms of dyspnea or fever and rigors develop.
Claudius I, Baraff LJ. Pediatric emergencies associated with fever. Emerg Med Clin North Am. 2010 Feb. 28(1):67-84, vii-viii. [Medline].
Hussain AN, Kumar V. The lung. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran: Pathologic Basis of Disease. 7th ed. Philadelphia, Pa: Elsevier Saunders; 2005. 711-72.
[Guideline] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1. 44 Suppl 2:S27-72. [Medline].
Stedman's Medical Dictionary. 27th ed. Baltimore, Md: Lippincott, Williams and Wilkins; 2003.
Anand N, Kollef MH. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin Respir Crit Care Med. 2009 Feb. 30(1):3-9. [Medline].
El Solh AA. Nursing home-acquired pneumonia. Semin Respir Crit Care Med. 2009 Feb. 30(1):16-25. [Medline].
Kuti JL, Shore E, Palter M, Nicolau DP. Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines. Semin Respir Crit Care Med. 2009 Feb. 30(1):102-15. [Medline].
Eggimann P, Pittet D. Infection control in the ICU. Chest. 2001 Dec. 120(6):2059-93. [Medline].
Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005 Sep 15. 41(6):848-54. [Medline].
Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010 May 13. 362(19):1804-13. [Medline].
Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001 Mar 1. 344(9):665-71. [Medline].
Rubins JB, Janoff EN. Pneumolysin: a multifunctional pneumococcal virulence factor. J Lab Clin Med. 1998 Jan. 131(1):21-7. [Medline].
Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008 Oct 1. 198(7):962-70. [Medline]. [Full Text].
Forgie S, Marrie TJ. Healthcare-associated atypical pneumonia. Semin Respir Crit Care Med. 2009 Feb. 30(1):67-85. [Medline].
Centers for Disease Control and Prevention. Pneumonia. Available at http://www.cdc.gov/Features/Pneumonia/. Accessed: January 13, 2011.
Restrepo MI, Anzueto A. The role of gram-negative bacteria in healthcare-associated pneumonia. Semin Respir Crit Care Med. 2009 Feb. 30(1):61-6. [Medline].
Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep. 2009 Oct 2. 58(38):1071-4. [Medline].
2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care - New York City, 2009. MMWR Morb Mortal Wkly Rep. 2010 Mar 26. 59(11):321-6. [Medline].
Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001 Jun 6. 285(21):2763-73. [Medline].
Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002 Dec. 122(6):2115-21. [Medline].
American Lung Association. Trends in pneumonia and influenza morbidity and mortality. September 2008. American Lung Association. Available at http://bit.ly/gwYJAE. Accessed: January 13, 2011.
Kung HC, Hoyert DL, Xu JQ, Murphy SL, and the Division of Vital Statistics. Deaths: final data for 2005. National Vital Statistics Reports. Hyattsville, Md: National Center for Health Statistics April 2008: 56(10). http://www.cdc.gov. Available at http://bit.ly/i3ATH5. Accessed: January 13, 2011.
Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med. 1999 Jul 26. 107(1A):34S-43S. [Medline].
Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrús A, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011 Apr. 66(4):340-6. [Medline].
van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009 Oct 31. 374(9700):1543-56. [Medline].
Slovis BS, Brigham KL. Cecil Essentials of Medicine. : Andreoli T, Carpenter CCJ, Griggs RC, Loscalzo J. Approach to the patient with respiratory disease. 6th ed. WB Saunders Co: Philadelphia, Pa; 2004. 177-80.
Brown SM, Jones BE, Jephson AR, Dean NC. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med. 2009 Dec. 37(12):3010-6. [Medline]. [Full Text].
Fang WF, Yang KY, Wu CL, Yu CJ, Chen CW, Tu CY, et al. Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia. Crit Care. 2011 Jan 19. 15(1):R32. [Medline].
Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003 May. 58(5):377-82. [Medline]. [Full Text].
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997 Jan 23. 336(4):243-50. [Medline].
Agency for Healthcare Research and Quality. Pneumonia severity index calculator. Available at http://pda.ahrq.gov/clinic/psi/psicalc.asp. Accessed: January 13, 2011.
Sligl WI, Majumdar SR, Marrie TJ. Triaging severe pneumonia: what is the "score" on prediction rules?. Crit Care Med. 2009 Dec. 37(12):3166-8. [Medline].
Phua J, See KC, Chan YH, Widjaja LS, Aung NW, Ngerng WJ, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax. 2009 Jul. 64(7):598-603. [Medline].
Bloos F, Marshall JC, Dellinger RP, et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care. 2011 Mar 7. 15(2):R88. [Medline].
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct. 13(10):818-29. [Medline].
Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993 Dec 22-29. 270(24):2957-63. [Medline].
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996 Jul. 22(7):707-10. [Medline].
El-Solh AA, Alhajhusain A, Abou Jaoude P, Drinka P. Validity of severity scores in hospitalized patients with nursing home-acquired pneumonia. Chest. 2010 Dec. 138(6):1371-6. [Medline].
España PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006 Dec 1. 174(11):1249-56. [Medline].
Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M, Wunderink R. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med. 2009 Feb. 37(2):456-62. [Medline].
Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008 Aug 1. 47(3):375-84. [Medline].
Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, et al. Procalcitonin and C reactive protein in hospitalised adult patients with community acquired pneumonia, exacerbation of asthma and chronic obstructive pulmonary disease. Chest. 2010 Oct 28. [Medline].
Skerrett SJ. Diagnostic testing for community-acquired pneumonia. Clin Chest Med. 1999 Sep. 20(3):531-48. [Medline].
Smith PR. What diagnostic tests are needed for community-acquired pneumonia?. Med Clin North Am. 2001 Nov. 85(6):1381-96. [Medline].
Ketai L, Jordan K, Marom EM. Imaging infection. Clin Chest Med. 2008 Mar. 29(1):77-105, vi. [Medline].
Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003 Feb 20. 348(8):727-34. [Medline].
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8. 345(19):1368-77. [Medline].
Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med. 2009 Dec. 24(4):337-42. [Medline]. [Full Text].
Pirracchio R, Mateo J, Raskine L, Rigon MR, Lukaszewicz AC, Mebazaa A, et al. Can bacteriological upper airway samples obtained at intensive care unit admission guide empiric antibiotherapy for ventilator-associated pneumonia?. Crit Care Med. 2009 Sep. 37(9):2559-63. [Medline].
Gharib AM, Stern EJ. Radiology of pneumonia. Med Clin North Am. 2001 Nov. 85(6):1461-91, x. [Medline].
Tarver RD, Teague SD, Heitkamp DE, Conces DJ Jr. Radiology of community-acquired pneumonia. Radiol Clin North Am. 2005 May. 43(3):497-512, viii. [Medline].
Gotway MB, Reddy GP, Webb WR, Elicker BM, Leung JW. High-resolution CT of the lung: patterns of disease and differential diagnoses. Radiol Clin North Am. 2005 May. 43(3):513-42, viii. [Medline].
[Guideline] Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008 Jan. 34(1):17-60. [Medline]. [Full Text].
Arnold FW, LaJoie AS, Brock GN, Peyrani P, Rello J, Menéndez R, et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med. 2009 Sep 14. 169(16):1515-24. [Medline].
McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med. 2009 Sep 14. 169(16):1525-31. [Medline].
[Guideline] Centers for Medicare and Medicaid Services, Joint Commission. Specifications manual for national hospital inpatient quality measures. V. 2.6b. Manual download retrieved April 2009.
Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med. 2010 Sep. 38(9):1802-8. [Medline].
Lam AP, Wunderink RG. The role of MRSA in healthcare-associated pneumonia. Semin Respir Crit Care Med. 2009 Feb. 30(1):52-60. [Medline].
Centers for Disease Control and Prevention. H1N1 Flu: Updated CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States April 2009 - April 10, 2010. Available at http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm. Accessed: June 1, 2010.
1. Phillips D. ACIP changes pneumococcal vaccine interval in low-risk elderly. Medscape Medical News. WebMD Inc. Sept 4, 2015. Available at http://www.medscape.com/viewarticle/850564.
Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, et al. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015 Sep 4. 64 (34):944-7. [Medline].
Centers for Disease Control and Prevention. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012 Oct 12. 61:816-9. [Medline].
Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged =65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014 Sep 19. 63(37):822-5. [Medline]. [Full Text].
Bonten M, Bolkenbaas M, Huijts S, et al. Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Abstract no. 0541. Pneumonia 2014;3:95. Available at https://pneumonia.org.au/public/journals/22/PublicFolder/ABSTRACTBOOKMASTERforwebupdated20-3-14.pdf.
Tang KL, Eurich DT, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia. Arch Intern Med. 2011 Jul 11. 171(13):1193-8. [Medline].
Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010 May 1. 181(9):975-82. [Medline].
FDA requests boxed warnings on fluoroquinolone antimicrobial drugs: seeks to strengthen warnings concerning increased risk of tendinitis and tendon rupture [press release]. Silver Spring, Md: US Food and Drug Administration; July 8, 2008. FDA. Available at http://bit.ly/fkBFeA. Accessed: January 14, 2011.
Crane M. FDA OKs Telavancin for Patients With Bacterial Pneumonia Medscape Medical News. Jun 21 2013. Available at http://www.medscape.com/viewarticle/806750. Accessed: July 10, 2013.
US Food and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when linezolid (Zyvox®) is given to patients taking certain psychiatric medications. Available at http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm. Accessed: July 27, 2011.
Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS. The Sanford Guide to Antimicrobial Therapy: 2010. 40th ed. Sperryville, Va: Antimicrobial Therapy, Inc; 2009.
|Organism||First-Line Antimicrobials||Alternative Antimicrobials|
(MIC < 2 mcg/mL)
|Penicillin G, amoxicillin||Macrolide, cephalosporin (oral or parenteral), clindamycin, doxycycline, respiratory fluoroquinolone|
(MIC ≥2 mcg/mL)
|Agents chosen on the basis of sensitivity||Vancomycin, linezolid, high-dose amoxicillin (3 g/d with MIC ≤4 mcg/mL|
|Methicillin susceptible||Antistaphylococcal penicillin||Cefazolin, clindamycin|
|Methicillin resistant||Vancomycin, linezolid||Trimethoprim- sulfamethoxazole|
|Non–beta-lactamase producing||Amoxicillin||Fluoroquinolone, doxycycline, azithromycin, clarithromycin|
|Beta-lactamase producing||Second- or third-generation cephalosporin, amoxicillin/clavulanate||Fluoroquinolone, doxycycline, azithromycin, clarithromycin|
|Mycoplasma pneumoniae||Macrolide, tetracycline||Fluoroquinolone|
|Chlamydophila pneumoniae||Macrolide, tetracycline||Fluoroquinolone|
|Legionella species||Fluoroquinolone, azithromycin||Doxycycline|
|Francisella tularensis||Doxycycline||Gentamicin, streptomycin|
|Yersinia pestis||Streptomycin, gentamicin||Doxycycline, fluoroquinolone|
|Bacillus anthracis (inhalational)||Ciprofloxacin, levofloxacin, doxycycline||Other fluoroquinolones, beta-lactam (if susceptible), rifampin, clindamycin, chloramphenicol|
|Enterobacteriaceae||Third-generation cephalosporin, carbapenem||Beta-lactam/beta-lactamase inhibitor, fluoroquinolone|
|Pseudomonas aeruginosa||Antipseudomonal beta-lactam plus ciprofloxacin, levofloxacin, or aminoglycoside||Aminoglycoside plus ciprofloxacin or levofloxacin|
|Bordetella pertussis||Macrolide||Trimethoprim- sulfamethoxazole|
|Anaerobe (aspiration)||Beta-lactam/beta-lactamase inhibitor, clindamycin||Carbapenem|
|MIC = Minimal inhibitory concentration.|